Covaxin for Children: Study says robust safety, immunogenicity in 2-18 year old volunteers

Hyderabad, Dec 30: Bharat Biotech International Limited (BBIL), on Thursday announced that BBV152 (Covaxin), its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Bharat Biotech had conducted phase

Source: India News, India Breaking News, Latest news headlines in India – Oneindia News